Key Drivers
- High margins
- Strong FCF
- Elevated leverage
AIAI Summary
IDXX's durable, high‑margin consumables model is now contingent—near‑term investment thesis pivots from a “consumables-only” growth story to one that requires consistent InVueDx placement execution, faster software monetization, and preserved visit volumes to justify rich multiples. Actionable watch‑points: verify quarterly placement cadence vs. the 5,500–6,000 guidance, adoption/recurring revenue from PIMS/Vello and new assays, and management's buyback/cash policy as a buffer against sustained visit softness.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High margins
- •Strong FCF
- •Elevated leverage
IDXX delivers exceptional margins, ROE and free cash flow fueling buybacks, but meaningful leverage and very rich multiples raise liquidity and multiple-compression risks.
Price Behavior
Key Price Behavior Insights:
- •Below last month SMA
- •RSI oversold
- •Lower highs pattern
Price is in a short-term downtrend—trading below its last month SMA with RSI ~27 (oversold), near-term support ≈$571 and resistance $630–$650, so downside confirmed on a break below $571 while rallies must clear $630–$650 to regain momentum.
Series of lower highs since late
Sentiment & News
Key News Insights:
- •Diagnostics growth
- •Cloud software
- •Insider selling
IDEXX's March headlines point to accelerating diagnostics and cloud-software recurring revenue driving strong share gains and institutional interest, offset by mixed stake moves and notable insider sales.
Product and software momentum supports continued valuation upside, but insider sales and mixed institutional positioning create near-term confidence risk
Similar Companies in Healthcare
Other companies in the same sector with AI ratings